Evaluation of nonspreading Rift Valley fever virus as a vaccine vector using influenza virus hemagglutinin as a model antigen

N. Oreshkova, L.A.H.M. Cornelissen, C.A.M. de Haan, R.J.M. Moormann, J.A. Kortekaas

Research output: Contribution to journalArticleAcademicpeer-review

8 Citations (Scopus)

Abstract

Virus replicon particles are capable of infection, genome replication and gene expression, but are unable to produce progeny virions, rendering their use inherently safe. By virtue of this unique combination of features, replicon particles hold great promise for vaccine applications. We previously developed replicon particles of Rift Valley fever virus (RVFV) and demonstrated their high efficacy as a RVFV vaccine in the natural target species. We have now investigated the feasibility of using this nonspreading RVFV (NSR) as a vaccine vector using influenza virus hemagglutinin as a model antigen. NSR particles were designed to express either the full-length hemagglutinin of influenza A virus H1N1 (NSR-HA) or the respective soluble ectodomain (NSR-sHA). The efficacies of the two NSR vector vaccines, applied via either the intramuscular or the intranasal route, were evaluated. A single vaccination with NSR-HA protected all mice from a lethal challenge dose, while vaccination with NSR-sHA was not protective. Interestingly, whereas intramuscular vaccination elicited superior systemic immune responses, intranasal vaccination provided optimal clinical protection.
Original languageEnglish
Pages (from-to)5323-5329
JournalVaccine
Volume32
Issue number41
DOIs
Publication statusPublished - 2014

Fingerprint

Rift Valley fever virus
vector vaccines
Hemagglutinins
hemagglutinins
Orthomyxoviridae
replicon
Replicon
Vaccination
Vaccines
vaccination
antigens
Antigens
Virion
vaccines
Influenza A virus
lethal dose
rendering
virion
immune response
Genome

Keywords

  • rna recombination
  • rhesus macaques
  • in-vivo
  • protein
  • replication
  • epitope
  • nss

Cite this

Oreshkova, N. ; Cornelissen, L.A.H.M. ; de Haan, C.A.M. ; Moormann, R.J.M. ; Kortekaas, J.A. / Evaluation of nonspreading Rift Valley fever virus as a vaccine vector using influenza virus hemagglutinin as a model antigen. In: Vaccine. 2014 ; Vol. 32, No. 41. pp. 5323-5329.
@article{258d9f2435b84933a534b9dbe9792bcb,
title = "Evaluation of nonspreading Rift Valley fever virus as a vaccine vector using influenza virus hemagglutinin as a model antigen",
abstract = "Virus replicon particles are capable of infection, genome replication and gene expression, but are unable to produce progeny virions, rendering their use inherently safe. By virtue of this unique combination of features, replicon particles hold great promise for vaccine applications. We previously developed replicon particles of Rift Valley fever virus (RVFV) and demonstrated their high efficacy as a RVFV vaccine in the natural target species. We have now investigated the feasibility of using this nonspreading RVFV (NSR) as a vaccine vector using influenza virus hemagglutinin as a model antigen. NSR particles were designed to express either the full-length hemagglutinin of influenza A virus H1N1 (NSR-HA) or the respective soluble ectodomain (NSR-sHA). The efficacies of the two NSR vector vaccines, applied via either the intramuscular or the intranasal route, were evaluated. A single vaccination with NSR-HA protected all mice from a lethal challenge dose, while vaccination with NSR-sHA was not protective. Interestingly, whereas intramuscular vaccination elicited superior systemic immune responses, intranasal vaccination provided optimal clinical protection.",
keywords = "rna recombination, rhesus macaques, in-vivo, protein, replication, epitope, nss",
author = "N. Oreshkova and L.A.H.M. Cornelissen and {de Haan}, C.A.M. and R.J.M. Moormann and J.A. Kortekaas",
year = "2014",
doi = "10.1016/j.vaccine.2014.07.051",
language = "English",
volume = "32",
pages = "5323--5329",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier",
number = "41",

}

Evaluation of nonspreading Rift Valley fever virus as a vaccine vector using influenza virus hemagglutinin as a model antigen. / Oreshkova, N.; Cornelissen, L.A.H.M.; de Haan, C.A.M.; Moormann, R.J.M.; Kortekaas, J.A.

In: Vaccine, Vol. 32, No. 41, 2014, p. 5323-5329.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Evaluation of nonspreading Rift Valley fever virus as a vaccine vector using influenza virus hemagglutinin as a model antigen

AU - Oreshkova, N.

AU - Cornelissen, L.A.H.M.

AU - de Haan, C.A.M.

AU - Moormann, R.J.M.

AU - Kortekaas, J.A.

PY - 2014

Y1 - 2014

N2 - Virus replicon particles are capable of infection, genome replication and gene expression, but are unable to produce progeny virions, rendering their use inherently safe. By virtue of this unique combination of features, replicon particles hold great promise for vaccine applications. We previously developed replicon particles of Rift Valley fever virus (RVFV) and demonstrated their high efficacy as a RVFV vaccine in the natural target species. We have now investigated the feasibility of using this nonspreading RVFV (NSR) as a vaccine vector using influenza virus hemagglutinin as a model antigen. NSR particles were designed to express either the full-length hemagglutinin of influenza A virus H1N1 (NSR-HA) or the respective soluble ectodomain (NSR-sHA). The efficacies of the two NSR vector vaccines, applied via either the intramuscular or the intranasal route, were evaluated. A single vaccination with NSR-HA protected all mice from a lethal challenge dose, while vaccination with NSR-sHA was not protective. Interestingly, whereas intramuscular vaccination elicited superior systemic immune responses, intranasal vaccination provided optimal clinical protection.

AB - Virus replicon particles are capable of infection, genome replication and gene expression, but are unable to produce progeny virions, rendering their use inherently safe. By virtue of this unique combination of features, replicon particles hold great promise for vaccine applications. We previously developed replicon particles of Rift Valley fever virus (RVFV) and demonstrated their high efficacy as a RVFV vaccine in the natural target species. We have now investigated the feasibility of using this nonspreading RVFV (NSR) as a vaccine vector using influenza virus hemagglutinin as a model antigen. NSR particles were designed to express either the full-length hemagglutinin of influenza A virus H1N1 (NSR-HA) or the respective soluble ectodomain (NSR-sHA). The efficacies of the two NSR vector vaccines, applied via either the intramuscular or the intranasal route, were evaluated. A single vaccination with NSR-HA protected all mice from a lethal challenge dose, while vaccination with NSR-sHA was not protective. Interestingly, whereas intramuscular vaccination elicited superior systemic immune responses, intranasal vaccination provided optimal clinical protection.

KW - rna recombination

KW - rhesus macaques

KW - in-vivo

KW - protein

KW - replication

KW - epitope

KW - nss

U2 - 10.1016/j.vaccine.2014.07.051

DO - 10.1016/j.vaccine.2014.07.051

M3 - Article

VL - 32

SP - 5323

EP - 5329

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 41

ER -